Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial to Compare Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma

NCT07270991 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT07270991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07270991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial to Compare Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 3
Overall status
Recruiting
Start date
December 15, 2025
Completion date
November 30, 2030
Enrollment
324 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic oesogastric adenocarcinoma